Sanli Pharmaceuticals Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

1995

Location

Anshun Guizhou China

Primary Industry

Pharmaceuticals

About

Based in Guizhou, China and established in 1995, Sanli Pharmaceuticals is a medicine pharmaceutical companies that focuses on the research, development, manufacture and marketing of Chinese herbal drugs. In April 2020, Sanli Pharmaceuticals raised RMB 299.44 million in an IPO, sellings 40.74 million shares at RMB 7.35 per share on the Shanghai Stock Exchange. The company was awarded as national high-tech enterprise. The products of the company can be categorized into seven categories which are pediatrics, respiratory medicine, cardiovascular and cerebrovascular, bonesetter, rehabilitation, ophthalmology and gastroenterology. Products within include Kai throat spray, Ziheche capsule, Sanqi capsule, Huoxiang Zhengqi capsule, Naoliqing capsule, etc.

Current Investors

Huatai Securities, North Beta Capital, Ysun Investment

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Pharmaceuticals

Website

www.gz-sanli.com

Verticals

Manufacturing

Company Stage

Mature

Total Amount Raised

Subscriber access only

Deals

Deals Type
Buyout
PIPE
PIPE
PIPE
Buyout

Deal Status	Target (s)	Deal Date
Announced	Guiyang dechang xiang pharmaceutcal Co., Ltd.	06 Feb 2022
Completed	Sanli Pharmaceuticals	30 Sep 2021
Completed	Sanli Pharmaceuticals	30 Jun 2021
Completed	Sanli Pharmaceuticals	31 Mar 2021
Completed	Guiyang dechang xiang pharmaceutcal Co., Ltd.	22 Jul 2020

Displaying 1-5 of 5

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.